Committed to Making a Difference in the Lives of Patients
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives.
Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, rare disease endocrinology product candidates in clinical development. We have also established oncology as our second therapeutic area of focus.
TransCon Growth Hormone
TransCon Growth Hormone is being evaluated as a once-weekly therapy for children with growth hormone deficiency. Top-line results for our phase 3 heiGHt Trial are expected in the first quarter of 2019. Learn More
TransCon Technology Platform
Learn how we’re using our innovative TransCon technology (short from “transient conjugation”) to create best-in-class products to address unmet patient needs. Watch Video